Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease

Mediators of Inflammation

Volumn 12, Issue 4, 2003, Pages 251-253

  Gangemi, Sebastiano ^a   Basile, Giorgio ^b   Merendino, Rosaria Alba ^c   Epifanio, Antonio ^c   Pasquale, Giuseppe Di ^c   Ferlazzo, Benito ^a   Nicita Mauro, Vittorio ^b   Morgante, Letterio ^c  

^a Sch Div Allerg and Clin Immunol   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Interleukin 15; Levodopa; Parkinson's disease; RANTES

Indexed keywords

INTERLEUKIN 15; LEVODOPA; RANTES;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL DIFFERENTIATION; CELL GROWTH; CELL INFILTRATION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; INTERLEUKIN-15; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RANTES;

EID: 0142093530     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350310001599701     Document Type: Article

References (5)

1. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M. IL-1(, IL-2, IL-6 and TNF-( production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 1999; 53: 141-145.
2. Terreni L, De Simoni MG. Role of the brain in interleukin-6 modulation. Neuroimmunomodulation 1998; 5: 214-219.
3. Fehniger TA, Caligiuri MA. Interleukin-15: biology and relevance to human disease. Blood 2001; 97: 14-32.
4. Appay V, Rowland-Jones SL RANTES. a versatile and controversial chemokine. Trends Immunol 2001; 22: 83-87.
5. Perera LP, Goldman CK, Waldmann TA. IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J Immunol 1999; 162: 2606-2612.